Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313209726> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4313209726 endingPage "333" @default.
- W4313209726 startingPage "333" @default.
- W4313209726 abstract "Background and aim Brucellosis is one of the most common endemic zoonotic diseases that have large animal and human burden. Many regimens of drug combinations are used for a variable period (at least 6 weeks). Rifampicin with doxycycline is one of the most used combinations. In this respect, we aimed to compare between the efficacy of two different combinations: trimethoprim-sulfamethoxazole combined with doxycycline (TMX-Doxy) versus rifampicin combined with doxycycline (Rif-Doxy).Patient and methods Between June 2020 and January 2022, 100 patients with brucellosis were included. Half of them (50 patients) received TMX-Doxy, whereas the other half (50 patients) received Rif-Doxy for 6 weeks. Follow-up was done during the treatment course and 6 months after the end of treatment to detect successfully treated cases, failed-to-treat cases, and relapsed cases.Results The success rates of both used drug regimens were comparable, with the rate of success of TMX-Doxy combination being 90%, whereas it was 94% in the RIF-Doxy group (P=0.23). The failure rate was 4% in the TMX-Doxy group and 2% in the RIF-Doxy group (P=0.31). Relapse of brucellosis was recorded in 6% of patients in the TMX-Doxy group, whereas it was 4% of patients in the RIF-Doxy group (P=0.32). The adverse effects of both drug combinations were mild and self-limited, and none of the enrolled patients needed to stop treatment.Conclusion Combination of TMX-Doxy is effective, safe, and not inferior to the more used RIF-Doxy combination." @default.
- W4313209726 created "2023-01-06" @default.
- W4313209726 creator A5032266943 @default.
- W4313209726 creator A5054639954 @default.
- W4313209726 creator A5070502724 @default.
- W4313209726 date "2022-01-01" @default.
- W4313209726 modified "2023-09-26" @default.
- W4313209726 title "Doxycycline Plus Trimethoprim-Sulfamethoxazole versus Doxycycline plus Rifampicin in Treatment of Brucellosis: A Randomized Controlled Trial" @default.
- W4313209726 cites W1572137669 @default.
- W4313209726 cites W2778720477 @default.
- W4313209726 cites W4205390123 @default.
- W4313209726 doi "https://doi.org/10.4103/azmj.azmj_61_22" @default.
- W4313209726 hasPublicationYear "2022" @default.
- W4313209726 type Work @default.
- W4313209726 citedByCount "0" @default.
- W4313209726 crossrefType "journal-article" @default.
- W4313209726 hasAuthorship W4313209726A5032266943 @default.
- W4313209726 hasAuthorship W4313209726A5054639954 @default.
- W4313209726 hasAuthorship W4313209726A5070502724 @default.
- W4313209726 hasBestOaLocation W43132097261 @default.
- W4313209726 hasConcept C126322002 @default.
- W4313209726 hasConcept C141071460 @default.
- W4313209726 hasConcept C142724271 @default.
- W4313209726 hasConcept C168563851 @default.
- W4313209726 hasConcept C197934379 @default.
- W4313209726 hasConcept C203014093 @default.
- W4313209726 hasConcept C2777179404 @default.
- W4313209726 hasConcept C2778607973 @default.
- W4313209726 hasConcept C2779425571 @default.
- W4313209726 hasConcept C2780728791 @default.
- W4313209726 hasConcept C2781069245 @default.
- W4313209726 hasConcept C2781429187 @default.
- W4313209726 hasConcept C501593827 @default.
- W4313209726 hasConcept C71924100 @default.
- W4313209726 hasConcept C86803240 @default.
- W4313209726 hasConcept C89423630 @default.
- W4313209726 hasConceptScore W4313209726C126322002 @default.
- W4313209726 hasConceptScore W4313209726C141071460 @default.
- W4313209726 hasConceptScore W4313209726C142724271 @default.
- W4313209726 hasConceptScore W4313209726C168563851 @default.
- W4313209726 hasConceptScore W4313209726C197934379 @default.
- W4313209726 hasConceptScore W4313209726C203014093 @default.
- W4313209726 hasConceptScore W4313209726C2777179404 @default.
- W4313209726 hasConceptScore W4313209726C2778607973 @default.
- W4313209726 hasConceptScore W4313209726C2779425571 @default.
- W4313209726 hasConceptScore W4313209726C2780728791 @default.
- W4313209726 hasConceptScore W4313209726C2781069245 @default.
- W4313209726 hasConceptScore W4313209726C2781429187 @default.
- W4313209726 hasConceptScore W4313209726C501593827 @default.
- W4313209726 hasConceptScore W4313209726C71924100 @default.
- W4313209726 hasConceptScore W4313209726C86803240 @default.
- W4313209726 hasConceptScore W4313209726C89423630 @default.
- W4313209726 hasIssue "4" @default.
- W4313209726 hasLocation W43132097261 @default.
- W4313209726 hasOpenAccess W4313209726 @default.
- W4313209726 hasPrimaryLocation W43132097261 @default.
- W4313209726 hasRelatedWork W126286172 @default.
- W4313209726 hasRelatedWork W2023414062 @default.
- W4313209726 hasRelatedWork W2046824021 @default.
- W4313209726 hasRelatedWork W2057028957 @default.
- W4313209726 hasRelatedWork W2349044362 @default.
- W4313209726 hasRelatedWork W2396363297 @default.
- W4313209726 hasRelatedWork W2795564448 @default.
- W4313209726 hasRelatedWork W284226493 @default.
- W4313209726 hasRelatedWork W4200235252 @default.
- W4313209726 hasRelatedWork W4255038680 @default.
- W4313209726 hasVolume "20" @default.
- W4313209726 isParatext "false" @default.
- W4313209726 isRetracted "false" @default.
- W4313209726 workType "article" @default.